Global Biliary Tumor Market

Biliary Tumor Comprehensive Study by Type (Mecine, Surgery, Other), Application (Hospitals, Clinics, Other) Players and Region - Global Market Outlook to 2029

Biliary Tumor Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Biliary Tumor Market Scope
A biliary tumour, also known as bile duct cancer, is a kind of cancer that develops in the bile duct system. The system connects the liver, gallbladder, and small intestine, assisting in the movement of bile, a fluid that aids in the digestion of lipids. Biliary tumours are relatively rare, accounting for just around 2% of all cancers. Hepatocellular carcinoma and cholangiocarcinoma are the two forms of biliary tumours. Hepatocellular carcinoma is a type of cancer that arises in the liver and is more prevalent than other cancers. Cholangiocarcinoma is a tumour of the liver's biliary duct that is divided into intrahepatic biliary duct tumour and extrahepatic biliary duct tumour depending on where the tumour occurs. Primary sclerosing cholangitis (PSC), an inflammatory disorder of the intrahepatic or extrahepatic bile ducts, is the most common cause of cholangiocarcinoma. Biliary tract cancer comprises <1% of all human cancers and ∼10%–15% of all primary liver cancers.

AttributesDetails
Study Period2019-2029
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledF. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (United States), Teva Pharmaceutical Industries Ltd (Israel), Bristol-Myers Squibb Company (United States), Novartis AG (Switzerland), Eli Lilly and Company (United States), Mylan N.V. (United States), Fresenius Kabi AG (Germany), Intercept Pharmaceuticals (United States), Kyowa Kirin Co., Ltd. (Japan) and Johnson & Johnson Services, Inc. (United States)
CAGR%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Biliary Tumor market throughout the predicted period.

F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (United States), Teva Pharmaceutical Industries Ltd (Israel), Bristol-Myers Squibb Company (United States), Novartis AG (Switzerland), Eli Lilly and Company (United States), Mylan N.V. (United States), Fresenius Kabi AG (Germany), Intercept Pharmaceuticals (United States), Kyowa Kirin Co., Ltd. (Japan) and Johnson & Johnson Services, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Delcath Systems, Inc. (United States) and Accord Healthcare (United Kingdom).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Biliary Tumor market by Type , by Application (Hospitals, Clinics and Other) and Region with country level break-up.

On the basis of geography, the market of Biliary Tumor has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In September 2023, Boehringer Ingelheim acquired Alopexx Therapeutics, Inc., a biotech company developing targeted therapies for rare cancers, including intrahepatic cholangiocarcinoma (iCCA), a type of biliary tumor. This acquisition strengthens Boehringer Ingelheim's oncology portfolio and provides access to Alopexx's promising iCCA drug candidate.
In October 2023, AstraZeneca announced the launch of Imfinzi® (durvalumab) in combination with chemotherapy for unresectable biliary tract cancer (BTC). This approval provides a new treatment option for patients with advanced BTC, potentially improving survival outcomes.


Influencing Trend:
Increasing Incidencesof ,Diabetes, High Alcohol Consumption and Long Term Infection with Hepatitis B or Hepatitis C Virus

Market Growth Drivers:
Increasing Incidences of Gall Stones and Increasing Incidences of Bile Duct Stones in Obese Patient

Challenges:
Lack of Awareness in Some Countries

Restraints:
High Cost of Treatment

Opportunities:
Growing Research and Development Activities and Increased Investment in Drug Development

Key Target Audience
Service Providers, Healthcare Industry, Pharmaceutical Industry, Regulatory Bodies and Others

Report Objectives / Segmentation Covered

By Type
  • Mecine
  • Surgery
  • Other
By Application
  • Hospitals
  • Clinics
  • Other
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidences of Gall Stones
      • 3.2.2. Increasing Incidences of Bile Duct Stones in Obese Patient
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness in Some Countries
    • 3.4. Market Trends
      • 3.4.1. Increasing Incidencesof ,Diabetes, High Alcohol Consumption and Long Term Infection with Hepatitis B or Hepatitis C Virus
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Biliary Tumor, by Type, Application and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Biliary Tumor (Value)
      • 5.2.1. Global Biliary Tumor by: Type (Value)
        • 5.2.1.1. Mecine
        • 5.2.1.2. Surgery
        • 5.2.1.3. Other
      • 5.2.2. Global Biliary Tumor by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Other
      • 5.2.3. Global Biliary Tumor Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Biliary Tumor: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bristol-Myers Squibb Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mylan N.V. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Fresenius Kabi AG (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Intercept Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Kyowa Kirin Co., Ltd. (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Johnson & Johnson Services, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Biliary Tumor Sale, by Type, Application and Region (value) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Biliary Tumor (Value)
      • 7.2.1. Global Biliary Tumor by: Type (Value)
        • 7.2.1.1. Mecine
        • 7.2.1.2. Surgery
        • 7.2.1.3. Other
      • 7.2.2. Global Biliary Tumor by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Other
      • 7.2.3. Global Biliary Tumor Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Biliary Tumor: by Type(USD Million)
  • Table 2. Biliary Tumor Mecine , by Region USD Million (2018-2023)
  • Table 3. Biliary Tumor Surgery , by Region USD Million (2018-2023)
  • Table 4. Biliary Tumor Other , by Region USD Million (2018-2023)
  • Table 5. Biliary Tumor: by Application(USD Million)
  • Table 6. Biliary Tumor Hospitals , by Region USD Million (2018-2023)
  • Table 7. Biliary Tumor Clinics , by Region USD Million (2018-2023)
  • Table 8. Biliary Tumor Other , by Region USD Million (2018-2023)
  • Table 9. South America Biliary Tumor, by Country USD Million (2018-2023)
  • Table 10. South America Biliary Tumor, by Type USD Million (2018-2023)
  • Table 11. South America Biliary Tumor, by Application USD Million (2018-2023)
  • Table 12. Brazil Biliary Tumor, by Type USD Million (2018-2023)
  • Table 13. Brazil Biliary Tumor, by Application USD Million (2018-2023)
  • Table 14. Argentina Biliary Tumor, by Type USD Million (2018-2023)
  • Table 15. Argentina Biliary Tumor, by Application USD Million (2018-2023)
  • Table 16. Rest of South America Biliary Tumor, by Type USD Million (2018-2023)
  • Table 17. Rest of South America Biliary Tumor, by Application USD Million (2018-2023)
  • Table 18. Asia Pacific Biliary Tumor, by Country USD Million (2018-2023)
  • Table 19. Asia Pacific Biliary Tumor, by Type USD Million (2018-2023)
  • Table 20. Asia Pacific Biliary Tumor, by Application USD Million (2018-2023)
  • Table 21. China Biliary Tumor, by Type USD Million (2018-2023)
  • Table 22. China Biliary Tumor, by Application USD Million (2018-2023)
  • Table 23. Japan Biliary Tumor, by Type USD Million (2018-2023)
  • Table 24. Japan Biliary Tumor, by Application USD Million (2018-2023)
  • Table 25. India Biliary Tumor, by Type USD Million (2018-2023)
  • Table 26. India Biliary Tumor, by Application USD Million (2018-2023)
  • Table 27. South Korea Biliary Tumor, by Type USD Million (2018-2023)
  • Table 28. South Korea Biliary Tumor, by Application USD Million (2018-2023)
  • Table 29. Taiwan Biliary Tumor, by Type USD Million (2018-2023)
  • Table 30. Taiwan Biliary Tumor, by Application USD Million (2018-2023)
  • Table 31. Australia Biliary Tumor, by Type USD Million (2018-2023)
  • Table 32. Australia Biliary Tumor, by Application USD Million (2018-2023)
  • Table 33. Rest of Asia-Pacific Biliary Tumor, by Type USD Million (2018-2023)
  • Table 34. Rest of Asia-Pacific Biliary Tumor, by Application USD Million (2018-2023)
  • Table 35. Europe Biliary Tumor, by Country USD Million (2018-2023)
  • Table 36. Europe Biliary Tumor, by Type USD Million (2018-2023)
  • Table 37. Europe Biliary Tumor, by Application USD Million (2018-2023)
  • Table 38. Germany Biliary Tumor, by Type USD Million (2018-2023)
  • Table 39. Germany Biliary Tumor, by Application USD Million (2018-2023)
  • Table 40. France Biliary Tumor, by Type USD Million (2018-2023)
  • Table 41. France Biliary Tumor, by Application USD Million (2018-2023)
  • Table 42. Italy Biliary Tumor, by Type USD Million (2018-2023)
  • Table 43. Italy Biliary Tumor, by Application USD Million (2018-2023)
  • Table 44. United Kingdom Biliary Tumor, by Type USD Million (2018-2023)
  • Table 45. United Kingdom Biliary Tumor, by Application USD Million (2018-2023)
  • Table 46. Netherlands Biliary Tumor, by Type USD Million (2018-2023)
  • Table 47. Netherlands Biliary Tumor, by Application USD Million (2018-2023)
  • Table 48. Rest of Europe Biliary Tumor, by Type USD Million (2018-2023)
  • Table 49. Rest of Europe Biliary Tumor, by Application USD Million (2018-2023)
  • Table 50. MEA Biliary Tumor, by Country USD Million (2018-2023)
  • Table 51. MEA Biliary Tumor, by Type USD Million (2018-2023)
  • Table 52. MEA Biliary Tumor, by Application USD Million (2018-2023)
  • Table 53. Middle East Biliary Tumor, by Type USD Million (2018-2023)
  • Table 54. Middle East Biliary Tumor, by Application USD Million (2018-2023)
  • Table 55. Africa Biliary Tumor, by Type USD Million (2018-2023)
  • Table 56. Africa Biliary Tumor, by Application USD Million (2018-2023)
  • Table 57. North America Biliary Tumor, by Country USD Million (2018-2023)
  • Table 58. North America Biliary Tumor, by Type USD Million (2018-2023)
  • Table 59. North America Biliary Tumor, by Application USD Million (2018-2023)
  • Table 60. United States Biliary Tumor, by Type USD Million (2018-2023)
  • Table 61. United States Biliary Tumor, by Application USD Million (2018-2023)
  • Table 62. Canada Biliary Tumor, by Type USD Million (2018-2023)
  • Table 63. Canada Biliary Tumor, by Application USD Million (2018-2023)
  • Table 64. Mexico Biliary Tumor, by Type USD Million (2018-2023)
  • Table 65. Mexico Biliary Tumor, by Application USD Million (2018-2023)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Biliary Tumor: by Type(USD Million)
  • Table 78. Biliary Tumor Mecine , by Region USD Million (2024-2029)
  • Table 79. Biliary Tumor Surgery , by Region USD Million (2024-2029)
  • Table 80. Biliary Tumor Other , by Region USD Million (2024-2029)
  • Table 81. Biliary Tumor: by Application(USD Million)
  • Table 82. Biliary Tumor Hospitals , by Region USD Million (2024-2029)
  • Table 83. Biliary Tumor Clinics , by Region USD Million (2024-2029)
  • Table 84. Biliary Tumor Other , by Region USD Million (2024-2029)
  • Table 85. South America Biliary Tumor, by Country USD Million (2024-2029)
  • Table 86. South America Biliary Tumor, by Type USD Million (2024-2029)
  • Table 87. South America Biliary Tumor, by Application USD Million (2024-2029)
  • Table 88. Brazil Biliary Tumor, by Type USD Million (2024-2029)
  • Table 89. Brazil Biliary Tumor, by Application USD Million (2024-2029)
  • Table 90. Argentina Biliary Tumor, by Type USD Million (2024-2029)
  • Table 91. Argentina Biliary Tumor, by Application USD Million (2024-2029)
  • Table 92. Rest of South America Biliary Tumor, by Type USD Million (2024-2029)
  • Table 93. Rest of South America Biliary Tumor, by Application USD Million (2024-2029)
  • Table 94. Asia Pacific Biliary Tumor, by Country USD Million (2024-2029)
  • Table 95. Asia Pacific Biliary Tumor, by Type USD Million (2024-2029)
  • Table 96. Asia Pacific Biliary Tumor, by Application USD Million (2024-2029)
  • Table 97. China Biliary Tumor, by Type USD Million (2024-2029)
  • Table 98. China Biliary Tumor, by Application USD Million (2024-2029)
  • Table 99. Japan Biliary Tumor, by Type USD Million (2024-2029)
  • Table 100. Japan Biliary Tumor, by Application USD Million (2024-2029)
  • Table 101. India Biliary Tumor, by Type USD Million (2024-2029)
  • Table 102. India Biliary Tumor, by Application USD Million (2024-2029)
  • Table 103. South Korea Biliary Tumor, by Type USD Million (2024-2029)
  • Table 104. South Korea Biliary Tumor, by Application USD Million (2024-2029)
  • Table 105. Taiwan Biliary Tumor, by Type USD Million (2024-2029)
  • Table 106. Taiwan Biliary Tumor, by Application USD Million (2024-2029)
  • Table 107. Australia Biliary Tumor, by Type USD Million (2024-2029)
  • Table 108. Australia Biliary Tumor, by Application USD Million (2024-2029)
  • Table 109. Rest of Asia-Pacific Biliary Tumor, by Type USD Million (2024-2029)
  • Table 110. Rest of Asia-Pacific Biliary Tumor, by Application USD Million (2024-2029)
  • Table 111. Europe Biliary Tumor, by Country USD Million (2024-2029)
  • Table 112. Europe Biliary Tumor, by Type USD Million (2024-2029)
  • Table 113. Europe Biliary Tumor, by Application USD Million (2024-2029)
  • Table 114. Germany Biliary Tumor, by Type USD Million (2024-2029)
  • Table 115. Germany Biliary Tumor, by Application USD Million (2024-2029)
  • Table 116. France Biliary Tumor, by Type USD Million (2024-2029)
  • Table 117. France Biliary Tumor, by Application USD Million (2024-2029)
  • Table 118. Italy Biliary Tumor, by Type USD Million (2024-2029)
  • Table 119. Italy Biliary Tumor, by Application USD Million (2024-2029)
  • Table 120. United Kingdom Biliary Tumor, by Type USD Million (2024-2029)
  • Table 121. United Kingdom Biliary Tumor, by Application USD Million (2024-2029)
  • Table 122. Netherlands Biliary Tumor, by Type USD Million (2024-2029)
  • Table 123. Netherlands Biliary Tumor, by Application USD Million (2024-2029)
  • Table 124. Rest of Europe Biliary Tumor, by Type USD Million (2024-2029)
  • Table 125. Rest of Europe Biliary Tumor, by Application USD Million (2024-2029)
  • Table 126. MEA Biliary Tumor, by Country USD Million (2024-2029)
  • Table 127. MEA Biliary Tumor, by Type USD Million (2024-2029)
  • Table 128. MEA Biliary Tumor, by Application USD Million (2024-2029)
  • Table 129. Middle East Biliary Tumor, by Type USD Million (2024-2029)
  • Table 130. Middle East Biliary Tumor, by Application USD Million (2024-2029)
  • Table 131. Africa Biliary Tumor, by Type USD Million (2024-2029)
  • Table 132. Africa Biliary Tumor, by Application USD Million (2024-2029)
  • Table 133. North America Biliary Tumor, by Country USD Million (2024-2029)
  • Table 134. North America Biliary Tumor, by Type USD Million (2024-2029)
  • Table 135. North America Biliary Tumor, by Application USD Million (2024-2029)
  • Table 136. United States Biliary Tumor, by Type USD Million (2024-2029)
  • Table 137. United States Biliary Tumor, by Application USD Million (2024-2029)
  • Table 138. Canada Biliary Tumor, by Type USD Million (2024-2029)
  • Table 139. Canada Biliary Tumor, by Application USD Million (2024-2029)
  • Table 140. Mexico Biliary Tumor, by Type USD Million (2024-2029)
  • Table 141. Mexico Biliary Tumor, by Application USD Million (2024-2029)
  • Table 142. Research Programs/Design for This Report
  • Table 143. Key Data Information from Secondary Sources
  • Table 144. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Biliary Tumor: by Type USD Million (2018-2023)
  • Figure 5. Global Biliary Tumor: by Application USD Million (2018-2023)
  • Figure 6. South America Biliary Tumor Share (%), by Country
  • Figure 7. Asia Pacific Biliary Tumor Share (%), by Country
  • Figure 8. Europe Biliary Tumor Share (%), by Country
  • Figure 9. MEA Biliary Tumor Share (%), by Country
  • Figure 10. North America Biliary Tumor Share (%), by Country
  • Figure 11. Global Biliary Tumor share by Players 2023 (%)
  • Figure 12. Global Biliary Tumor share by Players (Top 3) 2023(%)
  • Figure 13. Global Biliary Tumor share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 16. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 17. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 19. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 20. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2023
  • Figure 21. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 22. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 23. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 25. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 27. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Mylan N.V. (United States) Revenue: by Geography 2023
  • Figure 29. Fresenius Kabi AG (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Fresenius Kabi AG (Germany) Revenue: by Geography 2023
  • Figure 31. Intercept Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 32. Intercept Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 33. Kyowa Kirin Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Kyowa Kirin Co., Ltd. (Japan) Revenue: by Geography 2023
  • Figure 35. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Global Biliary Tumor: by Type USD Million (2024-2029)
  • Figure 38. Global Biliary Tumor: by Application USD Million (2024-2029)
  • Figure 39. South America Biliary Tumor Share (%), by Country
  • Figure 40. Asia Pacific Biliary Tumor Share (%), by Country
  • Figure 41. Europe Biliary Tumor Share (%), by Country
  • Figure 42. MEA Biliary Tumor Share (%), by Country
  • Figure 43. North America Biliary Tumor Share (%), by Country
List of companies from research coverage that are profiled in the study
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Pfizer Inc. (United States)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Bristol-Myers Squibb Company (United States)
  • Novartis AG (Switzerland)
  • Eli Lilly and Company (United States)
  • Mylan N.V. (United States)
  • Fresenius Kabi AG (Germany)
  • Intercept Pharmaceuticals (United States)
  • Kyowa Kirin Co., Ltd. (Japan)
  • Johnson & Johnson Services, Inc. (United States)
Additional players considered in the study are as follows:
Delcath Systems, Inc. (United States) , Accord Healthcare (United Kingdom)
Select User Access Type

Key Highlights of Report


Jan 2024 217 Pages 74 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Biliary Tumor Market Quantitative research analysis
Global Biliary Tumor Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Biliary Tumor Market are by type [Mecine, Surgery and Other], by end use application [Hospitals, Clinics and Other].
The Biliary Tumor Market is gaining popularity and expected to see strong valuation by 2029.
  • Increasing Incidences of Gall Stones
  • Increasing Incidences of Bile Duct Stones in Obese Patient

Know More About Global Biliary Tumor Market Report?

Have a Query? Click Here

Other Related Reports

Neutropenia Treatment Comprehensive Study by Type (Granulocyte -colony-stimulating factor (G-CSF), Antibiotics, Antifungal drugs), Disease Type (Cyclic neutropenia, Kostmann’s syndrome, Chronic idiop...
$ 3750
Omnitrope Comprehensive Study by Type (Injection, Oral), Application (Hospital, Medical Center, Others), Medical Conditions (Hormone Deficiency, Chronic Kidney Disease, Idiopathic Short Stature, Noon...
$ 3450
Artificial Tendons and Ligaments Comprehensive Study by Application (Knee Injuries, Shoulder Injuries, Foot and Ankle Injuries, Others), Implant Type (Silastic-Rod Implant, Carbon-Fiber Implant, Marl...
$ 3750
Atherosclerosis Comprehensive Study by Treatment (Medication, Catheter-based Procedures (Balloon angioplasty, Atherectomy), Surgery (Endarterectomy, Arterioplasty, Bypass)), Distribution Channel (Hos...
$ 3450
Blood Coagulants Comprehensive Study by Type (Aprotinin, Tranexamic Acid (TXA), Epsilon-Aminocaproic acid, Aminomethylbenzoic acid, Other), Application (Hemophilia, Surgery (Post-Operative Care), Men...
$ 3750
Dural Repair Comprehensive Study by Type (Sheets, Patches, Plugs, Glues, Others), Application (Neurosurgery, Spine Surgery, Maxillofacial Surgery, Others), End Users (Hospitals, Clinics, Research Ins...
$ 3500